Back Article

Adler S P, Marshall B. Cytomegalovirus in-fections[J]. Pediatr Rev, 2007, 28(): 92-100. doi: 10.1542/pir.28-3-92

Ahn K, Angulo A, Ghazal P. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process[J]. Proc Natl Acad Sci USA, 1996, 93(): 10990-10995. doi: 10.1073/pnas.93.20.10990

Ahn K, Gruhler A, Galocha B. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP[J]. Immunity, 1997, 6(): 613-621. doi: 10.1016/S1074-7613(00)80349-0

Arase H, Mocarski E S, Campbell A E. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors[J]. Science, 2002, 296(): 1323-1326. doi: 10.1126/science.1070884

Askin D F. Intrauterine infections[J]. Neonatal Netw, 2004, 23(): 23-30. doi: 10.1891/0730-0832.23.5.23

Atreya I, Atreya R, Neurath M F. NF-kappaB in inflammatory bowel disease[J]. J Intern Med, 2008, 263(): 591-596. doi: 10.1111/j.1365-2796.2008.01953.x

Bale J F. Congenital infections[J]. Neurol Clin, 2002, 20(): 1039-1060. doi: 10.1016/S0733-8619(02)00014-2

Bason C, Corrocher R, Lunardi C. Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis[J]. Lancet, 2003, 362(): 1971-1977. doi: 10.1016/S0140-6736(03)15016-7

Basta S, Bennink J R. A survival game of hide and seek: cytomegaloviruses and MHC class Ⅰ antigen presentation pathways[J]. Viral Immunol, 2003, 16(): 231-242. doi: 10.1089/088282403322396064

Bauer D, Tampe R. Herpes viral proteins blocking the transporter associated with antigen processing TAP--from genes to function and structure[J]. Curr Top Micro-biol Immunol, 2002, 269(): 87-99.

Bego M G, St Jeor S. Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency[J]. Exp Hematol, 2006, 34(): 555-570. doi: 10.1016/j.exphem.2005.11.012

Beisser P S, Goh C S, Cohen F E. Viral chemokine receptors and chemokines in human cytomega-lovirus trafficking and interaction with the immune system. CMV chemokine receptors[J]. Curr Top Microbiol Im-munol, 2002, 269(): 203-34.

Bentz G L, Yurochko A D. Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins[J]. Proc Natl Acad Sci USA, 2008, 105(): 5531-5536. doi: 10.1073/pnas.0800037105

Boomker J M, de Jong E K, de Leij L F. Chemokine scavenging by the human cytomegalovirus chemokine decoy receptor US28 does not inhibit monocyte adherence to activated endothelium[J]. Antiviral Res, 2006, 69(): 124-127. doi: 10.1016/j.antiviral.2005.11.003

Boomker J M, van Luyn M J, The T H. US28 actions in HCMV infection: lessons from a versa-tile hijacker[J]. Rev Med Virol, 2005, 15(): 269-282. doi: 10.1002/(ISSN)1099-1654

Braud V M, Tomasec P, Wilkinson G W. Viral evasion of natural killer cells during human cytomega-lovirus infection[J]. Curr Top Microbiol Immunol, 2002, 269(): 117-129.

Bryant P, Morley C, Garland S. Cytomega-lovirus transmission from breast milk in premature babies: does it matter?[J]. Arch Dis Child Fetal Neonatal Ed, 2002, 87(): F75-77. doi: 10.1136/fn.87.2.F75

Candore G, Balistreri C R, Colonna-Romano G. Immunosenescence and anti-immunosenescence therapies: the case of probiotics[J]. Rejuvenation Res, 2008, 11(): 425-432. doi: 10.1089/rej.2008.0662

Chalupny N J, Rein-Weston A, Dosch S. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142[J]. Biochem Biophys Res Commun, 2006, 346(): 175-181. doi: 10.1016/j.bbrc.2006.05.092

Chang M, Pan M R, Chen D Y. Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice[J]. Clin Exp Immunol, 2006, 143(): 167-179. doi: 10.1111/cei.2006.143.issue-1

Chapman T L, Heikeman A P, Bjorkman P J. The inhibitory receptor LIR-1 uses a common binding interac-tion to recognize class Ⅰ MHC molecules and the viral homolog UL18[J]. Immunity, 1999, 11(): 603-613. doi: 10.1016/S1074-7613(00)80135-1

Cosman D, Mullberg J, Sutherland C L. ULBPs, novel MHC class Ⅰ-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor[J]. Immunity, 2001, 14(): 123-133. doi: 10.1016/S1074-7613(01)00095-4

Criscuoli V, Rizzuto M R, Cottone M. Cytomega-lovirus and inflammatory bowel disease: is there a link?[J]. World J Gastroenterol, 2006, 12(): 4813-4818.

Damato E G, Winnen C W. Cytomegalovirus infection: perinatal implications[J]. J Obstet Gynecol Neo-natal Nurs, 2002, 31(): 86-92. doi: 10.1111/j.1552-6909.2002.tb00026.x

Davison A J, Dolan A, Akter P. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome[J]. J Gen Virol, 2003, 84(): 17-28. doi: 10.1099/vir.0.18606-0

DeFilippis V R. Induction and evasion of the type Ⅰ interferon response by cytomegaloviruses[J]. Adv Exp Med Biol, 2007, 598(): 309-24. doi: 10.1007/978-0-387-71767-8

Diaz F, Urkijo J C, Mendoza F. Systemic lupus erythematosus associated with acute cytomega-lovirus infection[J]. J Clin Rheumatol, 2006, 12(): 263-264. doi: 10.1097/01.rhu.0000239832.74804.17

Dimitroulia E, Spanakis N, Konstantinidou A E. Frequent detection of cytomegalovirus in the in-testine of patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2006, 12(): 879-884. doi: 10.1097/01.mib.0000231576.11678.57

Dugan G E, Hewitt E W. Structural and Func-tional Dissection of the Human Cytomegalovirus Immune Evasion Protein US6[J]. J Virol, 2008, 82(): 3271-3282. doi: 10.1128/JVI.01705-07

Dunn C, Chalupny N J, Sutherland C L. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity[J]. J Exp Med, 2003, 197(): 1427-1439. doi: 10.1084/jem.20022059

Dunn W, Chou C, Li H. Functional profiling of a human cytomegalovirus genome[J]. Proc Natl Acad Sci USA, 2003, 100(): 14223-14228. doi: 10.1073/pnas.2334032100

Editorial Comments. Cytomegalovirus[J]. Am J Transplant, 2004, 4(Suppl 10): 51-58.

Emery V C. Cytomegalovirus and the aging popu-lation[J]. Drugs Aging, 2001, 18(): 927-933. doi: 10.2165/00002512-200118120-00004

Emery V C. Investigation of CMV disease in immunocompromised patients[J]. J Clin Pathol, 2001, 54(): 84-88. doi: 10.1136/jcp.54.2.84

Franceschi C. Inflammaging as a major charac-teristic of old people: can it be prevented or cured?[J]. Nutr Rev, 2007, 65(): S173-176.

Franceschi C, Bonafe M. Centenarians as a model for healthy aging[J]. Biochem Soc Trans, 2003, 31(): 457-61. doi: 10.1042/bst0310457

Froberg M K. Review: CMV escapes![J]. Ann Clin Lab Sci, 2004, 34(): 123-130.

Gewurz B E, Gaudet R, Tortorella D. Antigen presentation subverted: Structure of the human cytomegalovirus protein US2 bound to the class Ⅰ mo-lecule HLA-A2[J]. Proc Natl Acad Sci USA, 2001, 98(): 6794-6799. doi: 10.1073/pnas.121172898

Giunta S. Is inflammaging an auto[innate] immunity subclinical syndrome?[J]. Immun Ageing, 2006, 3(): 12-. doi: 10.1186/1742-4933-3-12

Gold E, Nankervis G A. 1976. Cytomegalovirus. In: Viral infections of humans: epidemiology and control (Evans A S ed.), Plenum Press: New York, p 143-161.

Goldmacher V S. Cell death suppression by cytomegaloviruses[J]. Apoptosis, 2005, 10(): 251-265. doi: 10.1007/s10495-005-0800-z

Goldmacher V S. vMIA, a viral inhibitor of apo-ptosis targeting mitochondria[J]. Biochimie, 2002, 84(): 177-185. doi: 10.1016/S0300-9084(02)01367-6

Hengel H, Koopmann J O, Flohr T. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter[J]. Immunity, 1997, 6(): 623-632. doi: 10.1016/S1074-7613(00)80350-7

Hommes D W, Sterringa G, van Deventer S J. The pathogenicity of cytomegalovirus in inflam-matory bowel disease: a systematic review and evidence-based recommendations for future research[J]. Inflamm Bowel Dis, 2004, 10(): 245-250. doi: 10.1097/00054725-200405000-00011

Hooper M, Kallas E G, Coffin D. Cytomega-lovirus seropositivity is associated with the expansion of CD4⁺CD28^- and CD8⁺CD28^- T cells in rheumatoid arthritis[J]. J Rheumatol, 1999, 26(): 1452-1457.

Hrycek A, Kusmierz D, Mazurek U. Human cytomegalovirus in patients with systemic lupus ery-thematosus[J]. Autoimmunity, 2005, 38(): 487-491. doi: 10.1080/08916930500285667

Hussein K, Hayek T, Yassin K. Acute cytomegalovirus infection associated with the onset of inflammatory bowel disease[J]. Am J Med Sci, 2006, 331(): 40-43. doi: 10.1097/00000441-200601000-00012

Jarvis M A, Borton J A, Keech A M. Human cytomegalovirus attenuates interleukin-1beta and tumor necrosis factor alpha proinflammatory signaling by inhibition of NF-kappaB activation[J]. J Virol, 2006, 80(): 5588-5598. doi: 10.1128/JVI.00060-06

Jarvis M A, Nelson J A. Human cytomegalovirus persistence and latency in endothelial cells and macrop-hages[J]. Curr Opin Microbiol, 2002, 5(): 403-407. doi: 10.1016/S1369-5274(02)00334-X

Jarvis M A, Nelson J A. Mechanisms of human cytomegalovirus persistence and latency[J]. Front Biosci, 2002, 7(): d1575-1582. doi: 10.2741/A862

Jenkins C, Abendroth A, Slobedman B. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection[J]. J Virol, 2004, 78(): 1440-1447. doi: 10.1128/JVI.78.3.1440-1447.2004

Johnson D C, Hegde N R. Inhibition of the MHC class Ⅱ antigen presentation pathway by human cytomega-lovirus[J]. Curr Top Microbiol Immunol, 2002, 269(): 101-115.

Jones T R, Wiertz E J, Sun L. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class Ⅰ heavy chains[J]. Proc Natl Acad Sci USA, 1996, 93(): 11327-11333. doi: 10.1073/pnas.93.21.11327

Jurak I, Brune W. Induction of apoptosis limits cytomegalovirus cross-species infection[J]. Embo J, 2006, 25(): 2634-2642. doi: 10.1038/sj.emboj.7601133

Kanapeckiene V, Kalibatas J, Redaitiene E. The association between cytomegalovirus infection and aging process[J]. Medicina (Kaunas), 2007, 43(): 419-424.

Kavanagh D G, Hill A B. Evasion of cytotoxic T lymphocytes by murine cytomegalovirus[J]. Semin Im-munol, 2001, 13(): 19-26. doi: 10.1006/smim.2001.0292

Kerrey B T, Morrow A, Geraghty S. Breast milk as a source for acquisition of cytomegalovirus (HCMV) in a premature infant with sepsis syndrome: detection by real-time PCR[J]. J Clin Virol, 2006, 35(): 313-316. doi: 10.1016/j.jcv.2005.09.013

Khan N. The immunological burden of human cytomegalovirus infection[J]. Arch Immunol Ther Exp (Warsz), 2007, 55(): 299-308. doi: 10.1007/s00005-007-0037-3

Khan N, Hislop A, Gudgeon N. Herpes-virus-specific CD8 T cell immunity in old age: cytomega-lovirus impairs the response to a coresident EBV infection[J]. J Immunol, 2004, 173(): 7481-7489. doi: 10.4049/jimmunol.173.12.7481

Khan N, Shariff N, Cobbold M. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals[J]. J Immunol, 2002, 169(): 1984-1992. doi: 10.4049/jimmunol.169.4.1984

Khoshnevis M, Tyring S K. Cytomegalovirus infections[J]. Dermatol Clin, 2002, 20(): 291-299. doi: 10.1016/S0733-8635(01)00007-9

Kinney J S, Onorato I M, Stewart J A. Cytomegaloviral infection and disease[J]. J Infect Dis, 1985, 151(): 772-774. doi: 10.1093/infdis/151.5.772

Kojima T, Watanabe T, Hata K. Cytomega-lovirus infection in ulcerative colitis[J]. Scand J Gastroen-terol, 2006, 41(): 706-711. doi: 10.1080/00365520500408584

Koutouzov S, Jeronimo A L, Campos H. Nucleosomes in the pathogenesis of systemic lupus ery-thematosus[J]. Rheum Dis Clin North Am, 2004, 30(): 529-558. doi: 10.1016/j.rdc.2004.04.001

Krmpotic A, Bubic I, Polic B. Pathogenesis of murine cytomegalovirus infection[J]. Microbes Infect, 2003, 5(): 1263-1277. doi: 10.1016/j.micinf.2003.09.007

Landolfo S, Gariglio M, Gribaudo G. The human cytomegalovirus[J]. Pharmacol Ther, 2003, 98(): 269-297. doi: 10.1016/S0163-7258(03)00034-2

Lehner P J, Karttunen J T, Wilkinson G W. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation[J]. Proc Natl Acad Sci USA, 1997, 94(): 6904-6909. doi: 10.1073/pnas.94.13.6904

Lenac T, Arapovic J, Traven L. Murine cytomegalovirus regulation of NKG2D ligands[J]. Med Microbiol Immunol, 2008, 197(): 159-166. doi: 10.1007/s00430-008-0080-7

Lin A, Xu H, Yan W. Modulation of HLA expres-sion in human cytomegalovirus immune evasion[J]. Cell Mol Immunol, 2007, 4(): 91-98.

Lodoen M B, Abenes G, Umamoto S. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions[J]. J Exp Med, 2004, 200(): 1075-1081. doi: 10.1084/jem.20040583

Loenen W A, Bruggeman C A, Wiertz E J. Im-mune evasion by human cytomegalovirus: lessons in immunology and cell biology[J]. Semin Immunol, 2001, 13(): 41-49. doi: 10.1006/smim.2001.0294

Lunardi C, Bason C, Corrocher R. Induction of endothelial cell damage by hCMV molecular mimicry[J]. Trends Immunol, 2005, 26(): 19-24. doi: 10.1016/j.it.2004.10.009

Lunardi C, Bason C, Navone R. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells[J]. Nat Med, 2000, 6(): 1183-1186. doi: 10.1038/80533

Lunardi C, Dolcino M, Peterlana D. Antibodies against human cytomegalovirus in the patho-genesis of systemic sclerosis: a gene array approach[J]. PLoS Med, 2006, 3(): e2-.

Lunardi C, Dolcino M, Peterlana D. Endothelial cells' activation and apoptosis induced by a subset of antibodies against human cytomegalovirus: relevance to the pathogenesis of atherosclerosis[J]. PLoS ONE, 2007, 2(): e473-. doi: 10.1371/journal.pone.0000473

Mattey D L, Dawes P T, Nixon N B. Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease[J]. Ann Rheum Dis, 2004, 63(): 420-425. doi: 10.1136/ard.2003.008011

McCormick A L. Control of apoptosis by human cytomegalovirus[J]. Curr Top Microbiol Immunol, 2008, 325(): 281-295.

Mehraein Y, Lennerz C, Ehlhardt S. Latent Epstein-Barr virus (EBV) infection and cytomegalovirus (CMV) infection in synovial tissue of autoimmune chronic arthritis determined by RNA-and DNA-in situ hybridization[J]. Mod Pathol, 2004, 17(): 781-789. doi: 10.1038/modpathol.3800119

Mocarski E S. Immunomodulation by cytomega-loviruses: manipulative strategies beyond evasion[J]. Trends Microbiol, 2002, 10(): 332-339. doi: 10.1016/S0966-842X(02)02393-4

Mocarski E S. Courcelle, C. T. Cytomegalovirus and their replication, In: Fields' Virology (Knipe D M, Howley P M, ed. ), Lippincott : Philadelphia, p2629-2673.

Murphy E, Rigoutsos I, Shibuya T. Reevaluation of human cytomegalovirus coding potential[J]. Proc Natl Acad Sci USA, 2003, 100(): 13585-13590. doi: 10.1073/pnas.1735466100

Murphy E, Yu D, Grimwood J. Coding potential of laboratory and clinical strains of human cytomegalovirus[J]. Proc Natl Acad Sci USA, 2003, 100(): 14976-14981. doi: 10.1073/pnas.2136652100

Namboodiri A M, Rocca K M, Kuwana M. Antibodies to human cytomegalovirus protein UL83 in systemic sclerosis[J]. Clin Exp Rheumatol, 2006, 24(): 176-178.

Noyola D E, Valdez-Lopez B H, Hernandez-Salinas A E. Cytomegalovirus excretion in children attending day-care centers[J]. Arch Med Res, 2005, 36(): 590-593. doi: 10.1016/j.arcmed.2005.03.045

Pandey J P. Immunoglobulin GM genes and IgG antibodies to cytomegalovirus in patients with systemic sclerosis[J]. Clin Exp Rheumatol, 2004, 22(): S35-7.

Pass R F. 2001. Cytomegalovirus, In: Fields' Virology (Knipe D M, Howley P M ed. ), Lippincott: Philadelphia, p2675-2705.

Pass R F. Cytomegalovirus infection[J]. Pediatr Rev, 2002, 23(): 163-170. doi: 10.1542/pir.23-5-163

Pass R F. Epidemiology and transmission of cytomegalovirus[J]. J Infect Dis, 1985, 152(): 243-248. doi: 10.1093/infdis/152.2.243

Pawelec G, Gouttefangeas C. T-cell dysregulation caused by chronic antigenic stress: the role of CMV in immunosenescence?[J]. Aging Clin Exp Res, 2006, 18(): 171-173. doi: 10.1007/BF03327436

Pawelec G, Larbi A. Immunity and ageing in man: Annual Review 2006/2007[J]. Exp Gerontol, 2008, 43(): 34-38.

Peichl P, Scriba M, Haberhauer G. Selective binding of rheumatoid factors to antigen structures of cytomegalovirus (CMV)[J]. Scand J Rheumatol, 1988, Suppl 75(): 117-122.

Pereira L, Maidji E, McDonagh S. Insights into viral transmission at the uterine-placental interface[J]. Trends Microbiol, 2005, 13(): 164-174. doi: 10.1016/j.tim.2005.02.009

Plachter B, Sinzger C, Jahn G. Cell types in-volved in replication and distribution of human cytomega-lovirus[J]. Adv Virus Res, 1996, 46(): 195-261. doi: 10.1016/S0065-3527(08)60073-1

Rafailidis P I, Mourtzoukou E G, Varbobitis I C. Severe cytomegalovirus infection in apparently im-munocompetent patients: a systematic review[J]. Virol J, 2008, 5(): 47-. doi: 10.1186/1743-422X-5-47

Rahbar A, Bostrom L, Soderberg-Naucler C. Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn's disease[J]. J Autoimmun, 2006, 26(): 155-164. doi: 10.1016/j.jaut.2006.02.003

Rajagopalan S, Long E O. Viral evasion of NK-cell activation[J]. Trends Immunol, 2005, 26(): 403-405. doi: 10.1016/j.it.2005.06.008

Randolph-Habecker J R, Rahill B, Torok-Storb B. The expression of the cytomegalovirus chemokine receptor homolog US28 sequesters biologically active CC chemokines and alters IL-8 production[J]. Cytokine, 2002, 19(): 37-46. doi: 10.1006/cyto.2002.0874

Rawlinson W D, Farrell H E, Barrell B G. Analysis of the complete DNA sequence of murine cytomegalovirus[J]. J Virol, 1996, 70(): 8833-8849.

Reddehase M J, Podlech J, Grzimek N K. Mouse models of cytomegalovirus latency: overview[J]. J Clin Virol, 2002, 25(Suppl 2): S23-36.

Reeves M B, Lehner P J, Sissons J G. An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodelling[J]. J Gen Virol, 2005, 86(): 2949-2954. doi: 10.1099/vir.0.81161-0

Reeves M B, MacAry P A, Lehner P J. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers[J]. Proc Natl Acad Sci USA, 2005, 102(): 4140-4145. doi: 10.1073/pnas.0408994102

Reynolds D W, Stagno S, Alford C A. 1981. Chronic congenital and perinatal infections, In: Neonatal pathop-hysiolaogy and management in the newborn (Avery G B, ed. ). Lippincott : Philadelphia, p748-789.

Rezania D, Ouban A, Marcet J. CMV colitis mimicking recurrent inflammatory bowel disease: report of three cases[J]. Am Surg, 2007, 73(): 58-61.

Roback J D. CMV and blood transfusions[J]. Rev Med Virol, 2002, 12(): 211-219. doi: 10.1002/(ISSN)1099-1654

Robinson J. Infectious diseases in schools and child care facilities[J]. Pediatr Rev, 2001, 22(): 39-46. doi: 10.1542/pir.22-2-39

Ross S A, Boppana S B. Congenital cytomega-lovirus infection: outcome and diagnosis[J]. Semin Pediatr Infect Dis, 2005, 16(): 44-49. doi: 10.1053/j.spid.2004.09.011

Sansoni P, Vescovini R, Fagnoni F. The immune system in extreme longevity[J]. Exp Gerontol, 2008, 43(): 61-65. doi: 10.1016/j.exger.2007.06.008

Scalzo A A, Corbett A J, Rawlinson W D. The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection[J]. Immunol Cell Biol, 2007, 85(): 46-54. doi: 10.1038/sj.icb.7100013

Schleiss M R. Vertically transmitted herpesvirus infections[J]. Herpes, 2003, 10(): 4-11.

Sekigawa I, Nawata M, Seta N. Cytomega-lovirus infection in patients with systemic lupus ery-thematosus[J]. Clin Exp Rheumatol, 2002, 20(): 559-564.

Sinclair J. Human cytomegalovirus: Latency and reactivation in the myeloid lineage[J]. J Clin Virol, 2008, 41(): 180-185. doi: 10.1016/j.jcv.2007.11.014

Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus[J]. J Gen Virol, 2006, 87(): 1763-1779. doi: 10.1099/vir.0.81891-0

Sinzger C, Jahn G. Human cytomegalovirus cell tropism and pathogenesis[J]. Intervirology, 1996, 39(): 302-319. doi: 10.1159/000150502

Sissons J G, Bain M, Wills M R. Latency and reactivation of human cytomegalovirus[J]. J Infect, 2002, 44(): 73-77. doi: 10.1053/jinf.2001.0948

Skaletskaya A, Bartle L M, Chittenden T. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation[J]. Proc Natl Acad Sci USA, 2001, 98(): 7829-7834. doi: 10.1073/pnas.141108798

Smith H R, Heusel J W, Mehta I K. Recognition of a virus-encoded ligand by a natural killer cell activation receptor[J]. Proc Natl Acad Sci USA, 2002, 99(): 8826-8831. doi: 10.1073/pnas.092258599

Smith M G. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease[J]. Proc Soc Exp Biol Med, 1956, 92(): 424-440. doi: 10.3181/00379727-92-22498

Smith M G. Propagation of salivary gland virus of the mouse in tissue cultures[J]. Proc Soc Exp Biol Med, 1954, 86(): 435-440. doi: 10.3181/00379727-86-21123

Soderberg-Naucler C, Fish K N, Nelson J A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors[J]. Cell, 1997, 91(): 119-126. doi: 10.1016/S0092-8674(01)80014-3

Soderberg-Naucler C, Streblow D N, Fish K N. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent[J]. J Virol, 2001, 75(): 7543-7554. doi: 10.1128/JVI.75.16.7543-7554.2001

Stahl H D, Hubner B, Seidl B. Detection of multiple viral DNA species in synovial tissue and fluid of patients with early arthritis[J]. Ann Rheum Dis, 2000, 59(): 342-346. doi: 10.1136/ard.59.5.342

Staras S A, Dollard S C, Radford K W. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994[J]. Clin Infect Dis, 2006, 43(): 1143-1151. doi: 10.1086/508173

Streblow D N, Dumortier J, Moses A V. Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing[J]. Curr Top Microbiol Immunol, 2008, 325(): 397-415.

Sutherland C L, Chalupny N J, Schooley K. UL16-binding proteins, novel MHC class Ⅰ-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells[J]. J Immunol, 2002, 168(): 671-679. doi: 10.4049/jimmunol.168.2.671

Tang Q, Maul G G. Mouse cytomegalovirus crosses the species barrier with help from a few human cytomegalovirus proteins[J]. J Virol, 2006, 80(): 7510-7521. doi: 10.1128/JVI.00684-06

Terhune S, Torigoi E, Moorman N. Human cytomegalovirus UL38 protein blocks apoptosis[J]. J Virol, 2007, 81(): 3109-3123. doi: 10.1128/JVI.02124-06

Thompson J N. 1994. The Coevolutionary Process. University of Chicago Press: Chicago, USA.

Tsuchiya N, Murayama T, Yoshinoya S. Antibodies to human cytomegalovirus 65-kilodalton Fc binding protein in rheumatoid arthritis: idiotypic mimicry hypothesis of rheumatoid factor production[J]. Autoim-munity, 1993, 15(): 39-48. doi: 10.3109/08916939309004837

Vancikova Z, Dvorak P. Cytomegalovirus in-fection in immunocompetent and immunocompromised individuals--a review[J]. Curr Drug Targets Immune Endocr Metabol Disord, 2001, 1(): 179-187. doi: 10.2174/1568005310101020179

Vasto S, Colonna-Romano G, Larbi A. Role of persistent CMV infection in configuring T cell immunity in the elderly[J]. Immun Ageing, 2007, 4(): 2-. doi: 10.1186/1742-4933-4-2

Verdonk R C, Haagsma E B, Van Den Berg A P. Inflammatory bowel disease after liver trans-plantation: a role for cytomegalovirus infection[J]. Scand J Gastroenterol, 2006, 41(): 205-211. doi: 10.1080/00365520500206293

Vescovini R, Biasini C, Fagnoni F F. Massive load of functional effector CD4⁺ and CD8⁺ T cells against cytomegalovirus in very old subjects[J]. J Immunol, 2007, 179(): 4283-4291. doi: 10.4049/jimmunol.179.6.4283

Vink C, Beuken E, Bruggeman C A. Complete DNA sequence of the rat cytomegalovirus genome[J]. J Virol, 2000, 74(): 7656-7665. doi: 10.1128/JVI.74.16.7656-7665.2000

Vitale M, Castriconi R, Parolini S. The leukocyte Ig-like receptor (LIR)-1 for the cytomega-lovirus UL18 protein displays a broad specificity for different HLA class Ⅰ alleles: analysis of LIR-1 + NK cell clones[J]. Int Immunol, 1999, 11(): 29-35. doi: 10.1093/intimm/11.1.29

Voigt S, Mesci A, Ettinger J. Cytomega-lovirus evasion of innate immunity by subversion of the NKR-P1B:Clr-b missing-self axis[J]. Immunity, 2007, 26(): 617-627. doi: 10.1016/j.immuni.2007.03.013

Wagner C S, Ljunggren H G, Achour A. Immune modulation by the human cytomegalovirus-encoded molecule UL18, a mystery yet to be solved[J]. J Immunol, 2008, 180(): 19-24. doi: 10.4049/jimmunol.180.1.19

Waller E C, Day E, Sissons J G. Dynamics of T cell memory in human cytomegalovirus infection[J]. Med Microbiol Immunol, 2008, 197(): 83-96. doi: 10.1007/s00430-008-0082-5

Weller T H, Hanshaw J B, Scott D E. Serological differentiation of viruses responsible for cytomegalic inclusion disease[J]. Virology, 1960, 12(): 130-132. doi: 10.1016/0042-6822(60)90156-2

Wiertz E J, Jones T R, Sun L. The human cytomegalovirus US11 gene product dislocates MHC class Ⅰ heavy chains from the endoplasmic reticulum to the cytosol[J]. Cell, 1996, 84(): 769-779. doi: 10.1016/S0092-8674(00)81054-5

Woolhouse M E, Webster J P, Domingo E. Biological and biomedical implications of the co-evolution of pathogens and their hosts[J]. Nat Genet, 2002, 32(): 569-577. doi: 10.1038/ng1202-569

Yi L, Lin J Y, Gao Y. Detection of human cytomegalovirus in the atherosclerotic cerebral arteries in han population in china[J]. Acta Virol, 2008, 52(): 99-106.

Ziemann M, Krueger S, Maier A B. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion[J]. Transfusion, 2007, 47(): 1972-1983. doi: 10.1111/trf.2007.47.issue-11